GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Cyclically Adjusted PS Ratio

Viatris (Viatris) Cyclically Adjusted PS Ratio : 0.51 (As of Apr. 27, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Viatris Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Viatris's current share price is $11.57. Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $22.55. Viatris's Cyclically Adjusted PS Ratio for today is 0.51.

The historical rank and industry rank for Viatris's Cyclically Adjusted PS Ratio or its related term are showing as below:

VTRS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.37   Med: 1.69   Max: 5.23
Current: 0.51

During the past years, Viatris's highest Cyclically Adjusted PS Ratio was 5.23. The lowest was 0.37. And the median was 1.69.

VTRS's Cyclically Adjusted PS Ratio is ranked better than
85.73% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs VTRS: 0.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viatris's adjusted revenue per share data for the three months ended in Dec. 2023 was $3.169. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $22.55 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viatris Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Viatris's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Cyclically Adjusted PS Ratio Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.99 0.90 0.61 0.49 0.48

Viatris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.42 0.43 0.43 0.48

Competitive Comparison of Viatris's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PS Ratio falls into.



Viatris Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Viatris's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=11.57/22.55
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Viatris's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.169/129.4194*129.4194
=3.169

Current CPI (Dec. 2023) = 129.4194.

Viatris Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 4.325 99.695 5.615
201406 4.623 100.560 5.950
201409 5.245 100.428 6.759
201412 5.198 99.070 6.790
201503 4.217 99.621 5.478
201506 4.544 100.684 5.841
201509 5.244 100.392 6.760
201512 4.884 99.792 6.334
201603 4.300 100.470 5.539
201606 5.024 101.688 6.394
201609 5.839 101.861 7.419
201612 6.092 101.863 7.740
201703 5.065 102.862 6.373
201706 5.516 103.349 6.907
201709 5.563 104.136 6.914
201712 6.045 104.011 7.522
201803 5.194 105.290 6.384
201806 5.439 106.317 6.621
201809 5.542 106.507 6.734
201812 5.961 105.998 7.278
201903 4.846 107.251 5.848
201906 5.532 108.070 6.625
201909 5.738 108.329 6.855
201912 6.144 108.420 7.334
202003 5.066 108.902 6.020
202006 5.281 108.767 6.284
202009 5.741 109.815 6.766
202012 4.241 109.897 4.994
202103 3.669 111.754 4.249
202106 3.787 114.631 4.276
202109 3.741 115.734 4.183
202112 3.590 117.630 3.950
202203 3.455 121.301 3.686
202206 3.382 125.017 3.501
202209 3.348 125.227 3.460
202212 3.174 125.222 3.280
202303 3.093 127.348 3.143
202306 3.256 128.729 3.273
202309 3.264 129.860 3.253
202312 3.169 129.419 3.169

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viatris  (NAS:VTRS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Viatris Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Viatris's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (Viatris) Business Description

Industry
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
Andrew Cuneo officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni officer: President, Greater China 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury director, officer: Executive Chairman BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell director
Brian Roman officer: Global General Counsel 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro officer: See Remarks BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts director 120 PARK AVE, NEW YORK NY 10017
Melina E Higgins director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL